Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 1, 2015

BioPharm International

  • BioPharm International-02-01-2015
  • Volume 28
  • Issue 2

Colony Counter Increases Accuracy

Protos 3 is Synbiosis’ automated colony counter and chromogenic identification system.

 

Synbiosis’ automated colony counter and chromogenic identification system, Protos 3, is designed for walk-away colony counts in seconds and identifying microbial species by their color on chromogenic plates. The counter features a CCD camera with unique three-color LED lighting, which rapidly images an infinite number of colony colors on one plate and detects colonies as small as 0.043 mm.

The counter’s GLP-compliant software creates accurate counts and plate images and completes a full audit trail to eliminate errors.

Synbiosiswww.synbiosis.com

Articles in this issue

Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.